Friday, April 11, 2014

5 year-old autistic boy making steady gains after umbilical cord stem cell treatments

The following is a transcription of an interview with Anju and Selva R. regarding their son Ajay. Ajay was diagnosed Autism Spectrum Disorder (ASD) just before his second birthday in February 2011. Since that time, Ajay has received several courses of human umbilical cord-derived mesenchymal stem cells at the Stem Cell Institute.

"In general, his improvements have been so great that the school is advising a repeat assessment to see if he still fits under the diagnosis of ASD."

What kind of ASD symptoms did Ajay have before his stem cell treatments?

His symptoms included temper tantrums that resembled seizures lasting 30 to 45 minutes at a time. He was hyperactive and sometimes unintentionally violent in his play. He had very poor eye contact. He did not answer to his name. His dietary habits were very limited.

How has Ajay improved since his last round of treatments?

Thus far, he has had three Rx cycles at the Center: July, 2012 (age 3y-4mo), March 2013 (age 4y) and Feb 2014 (age 4y, 11 mo). Each time he showed rather sudden improvements in almost all areas of prior difficulties. After his first treatment, 90% of the tantrums disappeared within two weeks. His eye contact suddenly improved. He became much more aware of his surroundings - almost as if he just woke from a half sleep state. He started playing with his father for first time and with his twin somewhat. Transitions were much easier. Speech improved. He started greeting his therapists by name each day. We did not tell the therapists of the stem cell Rx as we wanted to get an unbiased feedback on his progress. They were rather surprised at the sudden change in his cognition and behavior. He still had some issues like not initiating play with his twin or other kids. His eye contact was much improved but not quite the same level as expected of his age group. Reciprocal conversation was also limited. After his second Rx he started to initiate play with his sib and other kids. Tantrums completely disappeared. Transition issues and general parental compliance improved. He started attending JK class in Sept 2014. He was assessed by a clinical psychologist for his post IBI evaluation in Oct 2014. Overall, he had showed considerable improvements, especially in non-verbal learning abilities as these were now on par as expected for normal kids his age (45’th percentile). However, his verbal learning abilities remained compromised (8’th percentile). His main limiting factors were his attention span and his diet remained somewhat limited. After his third Rx in Feb 2014, we have thus far noticed remarkable improvement in his diet. He is now eating sometimes even better than his normal twin. His language seems to be further along with more complex sentences. Hyperactivity and focus has also improved and we are only one month post Rx at the time of writing of this feedback. In general, his improvements have been so great that the school is advising a repeat assessment to see if he still fits under the diagnosis of ASD. We are awaiting an appointment for this some time later this year.

What kind of treatments and/or therapies did you try before coming to Panama for stem cell therapy?

Following the diagnosis, we attended parental workshops to help these types of kids with speech and other developmental issues. We began taking him daily to Ontario Early Years centers where Ajay could be exposed to other normal kids his age group so can join in on children’s activities. His speech improved a bit with this exposure. However, he would not play with the other children. Nine months after his diagnosis, he was accepted into the Themes Valley Autism Treatment program. They started sending in IBI therapists to work with Ajay for about 6 hours per weekday. He made a little bit further progress in language but eye contact remained extremely poor. Temper tantrums were still a major issue. Transitions remained very difficult. Diet remained very limited. He did not play with his normal (non-identical) twin or other kids.

How did you find the clinic and what made you decide upon the Stem Cell Institute?

We found the Panama clinic by researching for additional modalities of treatment. We reviewed some of the candid discussions and videos of families of former patients of the clinic. We queried the medical officers at the clinic to ensure cell samples were screened thoroughly for blood borne pathogens. We finally decided to go ahead with the treatment as Ajay clearly would not have had a very happy life if we continued with only behavioral therapy. We also were afraid he may unintentionally harm his normal twin due to his sudden violent movements and outbursts.

Stem Cell Institute Company Logo

Thursday, April 10, 2014

Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in New York City May 17th, 2014

New York, NY (PRWEB) April 09, 2014

The Stem Cell Institute, located in Panama City, Panama, will present an informational umbilical cord stem cell therapy seminar on Saturday, May 17, 2014 in New York City at the New York Hilton Midtown from 1:00 pm to 4:00 pm.

Speakers include:

Neil Riordan PhD“Clinical Trials: Umbilical Cord Mesenchymal Stem Cell Therapy for Autism and Spinal Cord Injury”

Dr. Riordan is the founder of the Stem Cell Institute and Medistem Panama Inc.

Jorge Paz-Rodriguez MD“Stem Cell Therapy for Autoimmune Disease: MS, Rheumatoid Arthritis and Lupus”

Dr. Paz is the Medical Director at the Stem Cell Institute. He practiced internal medicine in the United States for over a decade before joining the Stem Cell Institute in Panama.

Light snacks will be served afterwards. Our speakers and stem cell therapy patients will also be on hand to share their personal experiences and answer questions.

Admission is free but space in limited and registration is required. For venue information and to register and reserve your tickets today, please visit: http://www.eventbrite.com/e/stem-cell-institute-seminar-tickets-11115112601 or call Cindy Cunningham, Patient Events Coordinator, at 1 (800) 980-7836.

About Stem Cell Institute Panama
Founded in 2007 on the principles of providing unbiased, scientifically sound treatment options; the Stem Cell Institute (SCI) has matured into the world’s leading adult stem cell therapy and research center. In close collaboration with universities and physicians world-wide, our comprehensive stem cell treatment protocols employ well-targeted combinations of autologous bone marrow stem cells, autologous adipose stem cells, and donor human umbilical cord stem cells to treat: multiple sclerosis, spinal cord injury, osteoarthritis, rheumatoid arthritis, heart disease, and autoimmune diseases.

In partnership with Translational Biosciences, a subsidiary of Medistem Panama, SCI provides clinical services for ongoing clinical trials that are assessing safety and signs of efficacy for osteoarthritis, rheumatoid arthritis, and multiple sclerosis using allogeneic umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC), autologous stromal vascular fraction (SVF) and hU-MSC-derived mesenchymal trophic factors (MTF). In 2014, Translation Biosciences expects to expand its clinical trial portfolio to include spinal cord injury, heart disease, autism and cerebral palsy.

To-date, SCI has treated over 2000 patients.

For more information on stem cell therapy:

Stem Cell Institute Website: http://www.cellmedicine.com

Stem Cell Institute
Via Israel & Calle 66
Plaza Pacific Office #2A
Panama City, Panama

About Medistem Panama Inc.
Since opening its doors in 2007, Medistem Panama Inc. has developed adult stem cell-based products from human umbilical cord tissue and blood, adipose (fat) tissue and bone marrow. Medistem operates an 8000 sq. ft. ISO 9001-certified laboratory in the prestigious City of Knowledge. The laboratory is fully licensed by the Panamanian Ministry of Health and features 3 class 10000 clean rooms, class 100 laminar flow hoods, and class 100 incubators.

Medistem Panama Inc.
Ciudad del Saber, Edif. 221 / Clayton
Panama, Rep. of Panama

Phone: +507 306-2601
Fax: +507 306-2601

About Translational Biosciences
A subsidiary of Medistem Panama Inc., Translational Biosciences was founded solely to conduct clinical trials using adult stem cells and adult stem cell-derived products.

Translational Biosciences webSite: http://www.translationalbiosciences.com

Email: trials(at)translationalbiosciences(dot)com

Wednesday, April 9, 2014

Sam Harrell's Stem Cell Journey: Stem Cell Therapy for Multiple Sclerosis



Sam Harrell sent us this homemade video documenting his progress from 2010 until now (2014). Sam was coaching football at Ennis high school in Texas when MS struck him hard, forcing him to retire. Since then, after several rounds of stem cell therapy at the Stem Cell Institute in Panama, Sam has returned to coaching football, something he though that he would never be able to do again.

For more information about umbilical cord tissue-derived mesenchymal stem cell therapy for MS, please visit: http://www.cellmedicine.com/stem-cell-therapy-for-multiple-sclerosis-3/

Thursday, April 3, 2014

Umbilical Cord Stem Cell Therapy Clinical Trial for Multiple Sclerosis Gets Green Light

Translational Biosciences Site Header

Dallas, TX (PRWEB) April 03, 2014

Translational Biosciences, a subsidiary of Medistem Panama, has received the green light for a phase I/II clinical trial using human umbilical cord-derived mesenchymal stem cells (UC-MSC) for multiple sclerosis from the Comité Nacional de Bioética de la Investigación (CNEI) Institutional Review Board (IRB) in Panama.

According to the US National Multiple Sclerosis Society, in Multiple Sclerosis (MS), an abnormal immune-mediated T cell response attacks the myelin coating around nerve fibers in the central nervous system, as well as the nerve fibers themselves. This causes nerve impulses to slow or even halt, thus producing symptoms of MS that include fatigue; bladder and bowel problems; vision problems; and difficulty walking. The Cleveland Clinic reports that MS affects more than 350,000 people in the United States and 2.5 million worldwide.

Mesenchymal stem cells harvested from donated human umbilical cords after normal, healthy births possess anti-inflammatory and immune modulatory properties that may relieve MS symptoms. Because these cells are immune privileged, the recipient’s immune system does not reject them. These properties make UC-MSC interesting candidates for the treatment of multiple sclerosis and other autoimmune disorders.

Each patient will receive seven intravenous injections of UC-MSC over the course of 10 days. They will be assessed at 3 months and 12 months primarily for safety and secondarily for indications of efficacy.

The stem cell technology being utilized in this trial was developed by Neil Riordan, PhD, founder of Medistem Panama. The stem cells will be harvested and processed at Medistem Panama’s 8000 sq. ft. ISO-9001 certified laboratory in the prestigious City of Knowledge. They will be administered at the Stem Cell Institute in Panama City, Panama.

From his research laboratory in Dallas, Texas, Dr. Riordan commented, “Umbilical cord tissue provides an abundant, non-controversial supply of immune modulating mesenchymal stem cells. Preclinical and clinical research has demonstrated the anti-inflammatory and immune modulating effects of these cells. We look forward to the safety and efficacy data that will be generated by this clinical trial; the first in the western hemisphere testing the effects of umbilical cord mesenchymal stem cells on patients with multiple sclerosis.”

The Principle Investigator is Jorge Paz-Rodriguez, MD. Dr. Paz-Rodriguez also serves as the Medical Director at the Stem Cell Institute.

For detailed information about this clinical trial visit http://www.clinicaltrials.gov . If you are a multiple sclerosis patient between the ages of 18 and 55, you may qualify for this trial. Please email trials (at) translationalbiosciences (dot) com for more information about how to apply.

About Translational Biosciences

A subsidiary of Medistem Panama Inc., Translational Biosciences was founded solely to conduct clinical trials using adult stem cells and adult stem cell-derived products.

Translational Biosciences Web Site: http://www.translationalbiosciences.com
Email: trials@translationalbiosciences.com

About Medistem Panama Inc.

Since opening its doors in 2007, Medistem Panama Inc. has developed adult stem cell-based products from human umbilical cord tissue and blood, adipose (fat) tissue and bone marrow. Medistem operates an 8000 sq. ft. ISO 9001-certified laboratory in the prestigious City of Knowledge. The laboratory is fully licensed by the Panamanian Ministry of Health and features 3 class 10000 clean rooms, class 100 laminar flow hoods, and class 100 incubators.

Medistem Panama Inc.
Ciudad del Saber, Edif. 221 / Clayton
Panama, Rep. of Panama

Phone: +507 306-2601
Fax: +507 306-2601

About Stem Cell Institute Panama

Founded in 2007 on the principles of providing unbiased, scientifically sound treatment options; the Stem Cell Institute has matured into the world’s leading adult stem cell therapy and research center. In close collaboration with universities and physicians world-wide, our comprehensive stem cell treatment protocols employ well-targeted combinations of autologous bone marrow stem cells, autologous adipose stem cells, and donor human umbilical cord stem cells to treat: multiple sclerosis, spinal cord injury, osteoarthritis, rheumatoid arthritis, heart disease, and autoimmune diseases. To-date, the Institute has treated over 2000 patients.

For more information on stem cell therapy:
Stem Cell Institute Website: http://www.cellmedicine.com

Stem Cell Institute
Via Israel & Calle 66
Plaza Pacific Office #2A
Panama City, Panama